Pari L, Saravanan G
Department of Biochemistry, Faculty of Science, Annamalai University, Annamalai Nagar, 608 002, Tamil Nadu, India.
Comp Biochem Physiol C Toxicol Pharmacol. 2002 Jan;131(1):19-25. doi: 10.1016/s1532-0456(01)00259-9.
Cogent db, a compound herbal drug, was investigated for its possible antidiabetic effect in alloxan-induced diabetic rats. Oral administration of 0.15, 0.30 and 0.45 g/kg body wt. of the aqueous solution of Cogent db for 40 days exhibited a significant reduction in blood glucose, glycosylated haemoglobin and increased plasma insulin, total haemoglobin along with antihyperlipidemic effects in diabetic rats. The effective dose was found to be 0.45 g/kg body wt. It also prevents body weight loss in diabetic rats. An oral glucose tolerance test (OGTT) was also performed in experimental diabetic rats in which there was a significant improvement in glucose tolerance in rats treated with Cogent db. A comparison was made between the action of Cogent db and a known antidiabetic drug--glibenclamide (600 microg/kg body wt.). The antidiabetic effect of Cogent db was more effective than that observed with glibenclamide.
复方草药制剂Cogent db在四氧嘧啶诱导的糖尿病大鼠中进行了其可能的抗糖尿病作用研究。口服给予体重0.15、0.30和0.45 g/kg的Cogent db水溶液,持续40天,可使糖尿病大鼠的血糖、糖化血红蛋白显著降低,血浆胰岛素、总血红蛋白增加,并具有抗高血脂作用。有效剂量为体重0.45 g/kg。它还可防止糖尿病大鼠体重减轻。在实验性糖尿病大鼠中还进行了口服葡萄糖耐量试验(OGTT),结果显示用Cogent db治疗的大鼠葡萄糖耐量有显著改善。对Cogent db与一种已知的抗糖尿病药物——格列本脲(体重600微克/千克)的作用进行了比较。Cogent db的抗糖尿病作用比格列本脲更有效。